Study search
Go straight to the source
Search PubMed, Europe PMC and ClinicalTrials.gov from one box. Results come from the indexes themselves, newest first, each linked to its original record.
Amiravo's reviewed summary: Amycretin research reference →
24 records · open this search in PubMed
- PubMedReviewMedical treatments for obesity: what does the future have in store?The Journal of clinical endocrinology and metabolism · 2026 Oct 16
- PubMedSystematic ReviewReviewEfficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.Annals of internal medicine · 2026 Oct
- PubMedPeptide Marriages: Modular Assembly of Multi-Agonist Therapeutics.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026 Oct 1
- PubMedReviewNew Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026 Sep 28
- PubMedFuture GLP-1 receptor co-agonists and their cardiac effects.Naunyn-Schmiedeberg's archives of pharmacology · 2026 Sep 22
- PubMedReviewModern Obesity Treatment: Efficacy, Safety, and Future Directions of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonists.Cureus · 2026 Sep
- PubMedRandomized Controlled TrialMulticenter StudyClinical Trial, Phase IIEfficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.Lancet (London, England) · 2026 Aug 15
- PubMedRandomized Controlled TrialMulticenter StudyClinical Trial, Phase IIEfficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.Lancet (London, England) · 2026 Aug 15
- PubMedReviewBeyond weight loss: multisystem benefits of obesity medications.The lancet. Diabetes & endocrinology · 2026 Aug
- PubMedReviewObesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.Metabolism open · 2026 Jun
- PubMedReviewResearch Support, Non-U.S. Gov'tAmycretin in obesity: Mechanisms, clinical efficacy, and future perspectives.Metabolism: clinical and experimental · 2026 Jun
- PubMedNetwork Meta-AnalysisReviewNovel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis.Endocrinology, diabetes & metabolism · 2026 May
- PubMedReviewNovel GLP-1-based Medications for Type 2 Diabetes and Obesity.Endocrine reviews · 2026 Mar 11
- PubMedReviewLong-acting amylin-related peptides as therapies for obesity and type 2 diabetes.Peptides · 2026 Mar
- PubMedReviewAmylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies.Vascular pharmacology · 2026 Mar
- PubMedSynthetic target trial emulation and predictive modeling of amylin-pathway therapies for obesity and type 2 diabetes.Metabolism open · 2025 Dec
- PubMedReviewEfficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare.World journal of cardiology · 2025 Aug 26
- PubMedThe effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats.EBioMedicine · 2025 Aug
- PubMedGLP-1 and amylin receptor multiagonism with amycretin for obesity management.Lancet (London, England) · 2025 Jul 12
- PubMedRandomized Controlled TrialClinical Trial, Phase IClinical Trial, Phase IIAmycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.Lancet (London, England) · 2025 Jul 12
- PubMedRandomized Controlled TrialClinical Trial, Phase IResearch Support, Non-U.S. Gov'tSafety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial.Lancet (London, England) · 2025 Jul 12
- PubMedReviewMultifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.Peptides · 2025 May
- PubMedReviewComparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review.Cureus · 2025 Mar
- PubMedReviewManaging Post-Transplant Diabetes Mellitus after Kidney Transplantation: Challenges and Advances in Treatment.Pharmaceuticals (Basel, Switzerland) · 2024 Jul 26
Queries go directly from your browser to NCBI, EMBL-EBI and ClinicalTrials.gov; Amiravo does not store them. Study-type labels come from the indexes and can be wrong. A record's presence says nothing about whether a compound works or is safe. PubMed data via NCBI E-utilities; see NCBI policies.